- MorphoSys AG (NASDAQ: MOR) announced preliminary results from the ongoing Phase 1/2 study of tulmimetostat (CPI-0209) monotherapy in heavily pretreated patients with advanced cancers.
- The data showed responses or disease stabilization in five cohorts with evaluable patients.
- Four out of ten evaluable patients with ovarian clear cell carcinoma had a partial response, and three had stable disease.
- Five of eight evaluable patients with metastatic castration-resistant prostate cancer had stable disease.
- Two of the four evaluable patients with endometrial carcinoma had partial responses, one of whom later achieved a complete response after data cutoff, and two had stable disease.
- Two of the three evaluable patients with peripheral T-cell lymphoma had complete responses. There were two partial responses and four disease stabilizations for the nine evaluable patients with mesothelioma.
- The safety profile of tulmimetostat was consistent with the mechanism of action of EZH2 inhibition.
- The company also presented updated results from the Phase 1 dose-escalation portion of the trial, in which 41 patients were treated with oral tulmimetostat ranging from 50 mg to 375 mg daily.
- One dose-limiting toxicity of grade 4 thrombocytopenia was observed, which occurred at the highest dose.
- The disease control rate at 375 mg was 66.7%. Disease control was noted across doses except at 137.5 mg.
- Three of six patients in the 100 mg cohort had disease stabilization.
- Four of the seven patients in the 225 mg cohort had disease stabilization, and one with BAP-1 mutated mesothelioma had a partial response.
- Another partial response was noted in ARID1A-mutated endometrial carcinoma at 375 mg.
- Price Action: MOR shares are down 8.45% at $4.66 on the last check Friday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Read the original article on Benzinga
